Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 2Genital Diseases 1Endometrial Neoplasms 1Carcinoma, Endometrioid 1Breast Neoplasms 1

Interventions

Fulvestrant 58Trastuzumab 49Capecitabine 48Letrozole 45pembrolizumab 41Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37pertuzumab 36abemaciclib 36Blood Specimen Collection 31Specimen Handling 28trastuzumab deruxtecan 27Docetaxel 27Surveys and Questionnaires 26Anastrozole 25exemestane 24Tamoxifen 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 20Biopsy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × serabelisib × Clear all
NCT07558733 2026-04-30

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Faeth Therapeutics

Phase 1/2 Recruiting
32 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡